DOP2022000221A - Inhibidor de ret cristalino - Google Patents
Inhibidor de ret cristalinoInfo
- Publication number
- DOP2022000221A DOP2022000221A DO2022000221A DO2022000221A DOP2022000221A DO P2022000221 A DOP2022000221 A DO P2022000221A DO 2022000221 A DO2022000221 A DO 2022000221A DO 2022000221 A DO2022000221 A DO 2022000221A DO P2022000221 A DOP2022000221 A DO P2022000221A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- crystalline
- ret inhibitor
- ret
- crystalline form
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Semiconductor Lasers (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
En el presente documento se proporciona una forma cristalina de selpercatinib útil en el tratamiento y prevención de enfermedades que pueden tratarse con un inhibidor de la quinasa RET, incluidos enfermedades y trastornos asociados con RET, y métodos para preparar esta forma cristalina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063011701P | 2020-04-17 | 2020-04-17 | |
US202163151354P | 2021-02-19 | 2021-02-19 | |
PCT/US2021/026611 WO2021211380A1 (en) | 2020-04-17 | 2021-04-09 | Crystalline ret inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2022000221A true DOP2022000221A (es) | 2023-01-15 |
Family
ID=75747118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2022000221A DOP2022000221A (es) | 2020-04-17 | 2022-10-17 | Inhibidor de ret cristalino |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP4136090A1 (es) |
JP (1) | JP2023522012A (es) |
KR (1) | KR20230002706A (es) |
CN (1) | CN115916791A (es) |
AU (1) | AU2021255488B2 (es) |
BR (1) | BR112022020446A2 (es) |
CA (1) | CA3174316A1 (es) |
CL (1) | CL2022002849A1 (es) |
CO (1) | CO2022014882A2 (es) |
CR (1) | CR20220520A (es) |
DO (1) | DOP2022000221A (es) |
EC (1) | ECSP22080982A (es) |
IL (1) | IL297212A (es) |
MX (1) | MX2022012952A (es) |
PE (1) | PE20230388A1 (es) |
TW (1) | TW202202501A (es) |
WO (1) | WO2021211380A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022069357A1 (en) * | 2020-10-01 | 2022-04-07 | Sandoz Ag | Crystalline form of selpercatinib |
AU2022416156A1 (en) | 2021-12-13 | 2024-05-30 | Loxo Oncology, Inc. | Processes for the preparation of the crystalline form a of selpercatinib. a ret inhibitor |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
TWI791053B (zh) * | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TWI783057B (zh) * | 2017-10-10 | 2022-11-11 | 美商絡速藥業公司 | 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法 |
TWI812649B (zh) * | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
US20210379056A1 (en) * | 2018-09-30 | 2021-12-09 | Applied Pharmaceutical Science, Inc. | Substituted pyrazole fused ring derivative, preparation method therefor, and application thereof |
CN111004257B (zh) * | 2019-12-24 | 2021-06-29 | 武汉九州钰民医药科技有限公司 | 制备RET抑制剂Selpercatinib的方法 |
-
2021
- 2021-04-07 TW TW110112512A patent/TW202202501A/zh unknown
- 2021-04-09 JP JP2022562612A patent/JP2023522012A/ja active Pending
- 2021-04-09 BR BR112022020446A patent/BR112022020446A2/pt unknown
- 2021-04-09 CN CN202180043101.5A patent/CN115916791A/zh active Pending
- 2021-04-09 IL IL297212A patent/IL297212A/en unknown
- 2021-04-09 PE PE2022002417A patent/PE20230388A1/es unknown
- 2021-04-09 CR CR20220520A patent/CR20220520A/es unknown
- 2021-04-09 KR KR1020227039684A patent/KR20230002706A/ko active Search and Examination
- 2021-04-09 EP EP21722702.4A patent/EP4136090A1/en active Pending
- 2021-04-09 WO PCT/US2021/026611 patent/WO2021211380A1/en active Application Filing
- 2021-04-09 MX MX2022012952A patent/MX2022012952A/es unknown
- 2021-04-09 CA CA3174316A patent/CA3174316A1/en active Pending
- 2021-04-09 AU AU2021255488A patent/AU2021255488B2/en active Active
-
2022
- 2022-10-14 CL CL2022002849A patent/CL2022002849A1/es unknown
- 2022-10-17 DO DO2022000221A patent/DOP2022000221A/es unknown
- 2022-10-17 EC ECSENADI202280982A patent/ECSP22080982A/es unknown
- 2022-10-19 CO CONC2022/0014882A patent/CO2022014882A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230002706A (ko) | 2023-01-05 |
ECSP22080982A (es) | 2023-01-31 |
CL2022002849A1 (es) | 2023-06-16 |
AU2021255488A1 (en) | 2022-11-10 |
IL297212A (en) | 2022-12-01 |
JP2023522012A (ja) | 2023-05-26 |
AU2021255488B2 (en) | 2024-05-30 |
CA3174316A1 (en) | 2021-10-21 |
CR20220520A (es) | 2022-11-15 |
BR112022020446A2 (pt) | 2022-11-29 |
PE20230388A1 (es) | 2023-03-06 |
MX2022012952A (es) | 2023-01-11 |
TW202202501A (zh) | 2022-01-16 |
EP4136090A1 (en) | 2023-02-22 |
CN115916791A (zh) | 2023-04-04 |
CO2022014882A2 (es) | 2022-10-31 |
WO2021211380A1 (en) | 2021-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022014882A2 (es) | Inhibidor de ret cristalino | |
DOP2019000163A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
CL2018000119A1 (es) | Compuestos pirazolo[1,5-a]piridina sustituidos como inhibidores de quinasa de ret. | |
CL2018002708A1 (es) | Métodos para la inhibición de la angiogénesis en un sujeto que lo necesita | |
ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
CR20190218A (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
CR20150450A (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
CO2019001212A2 (es) | Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos | |
CO2021006075A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
ECSP11010824A (es) | Tratamiento para diabetes en pacientes inapropiados para terapia con metformina. | |
MX2022007221A (es) | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. | |
AR115583A1 (es) | Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado | |
ZA202006072B (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
DOP2023000145A (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
CO2021008535A2 (es) | Compuestos de quinolina como inhibidores de quinasas tam y met | |
AR104755A1 (es) | Método para el tratamiento de enfermedad neurológica | |
CO2019007879A2 (es) | Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización | |
CL2019000228A1 (es) | Tratamiento conjunto contra tipos de cáncer hematológico. | |
BR112022001393A2 (pt) | Forma cristalina do inibidor de atr e seu uso | |
DOP2018000197A (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer | |
CL2019002808A1 (es) | Métodos para prevenir o tratar enfermedades oftálmicas. | |
AR095594A1 (es) | Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos | |
CO2017005357A2 (es) | Un proceso para la fabricación de idalopirdina | |
CO2023017186A2 (es) | Formas cristalinas de trofinetida |